OCUP - Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics
- Ocuphire Pharma ( NASDAQ: OCUP ) on Wednesday said it had got a new U.S. patent extending the expiry and broadening the coverage of the company's late-stage oral product candidate APX3330.
- The U.S. Patent and Trademark Office issued patent no 11,351,130 to OCUP for APX3330 to treat inflammation and chronic pain in diabetic patients.
- The expiry for APX3330 was extended to 2038.
- OCUP is also evaluating APX3330 for the treatment of eye disease due to diabetes, including diabetic retinopathy and diabetic macular edema.
- The company expects results from an ongoing phase 2b trial of APX3330 for the treatment of diabetic retinopathy in H2 2022.
- OCUP also announced the publication of a peer-reviewed pre-clinical study in Frontiers in Oncology showing anti-inflammatory benefits of APX3330 for the treatment of a type of pancreatic cancer called pancreatic ductal adenocarcinoma.
- OCUP stock -1.5% at $1.93 in early trading.
For further details see:
Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics